MA46365A - Méthodes de traitement de troubles mitochondriaux et métaboliques - Google Patents
Méthodes de traitement de troubles mitochondriaux et métaboliquesInfo
- Publication number
- MA46365A MA46365A MA046365A MA46365A MA46365A MA 46365 A MA46365 A MA 46365A MA 046365 A MA046365 A MA 046365A MA 46365 A MA46365 A MA 46365A MA 46365 A MA46365 A MA 46365A
- Authority
- MA
- Morocco
- Prior art keywords
- mitochondrial
- treatment
- methods
- metabolic disorders
- metabolic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662401092P | 2016-09-28 | 2016-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46365A true MA46365A (fr) | 2019-08-07 |
Family
ID=61763007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046365A MA46365A (fr) | 2016-09-28 | 2017-09-28 | Méthodes de traitement de troubles mitochondriaux et métaboliques |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190307732A1 (fr) |
EP (1) | EP3518923A4 (fr) |
JP (2) | JP2019529474A (fr) |
KR (2) | KR102475256B1 (fr) |
CN (1) | CN110022876A (fr) |
AU (1) | AU2017335902B2 (fr) |
BR (1) | BR112019006113A2 (fr) |
CA (1) | CA3038824A1 (fr) |
CL (1) | CL2019000787A1 (fr) |
EA (1) | EA201990820A1 (fr) |
IL (1) | IL265566A (fr) |
MA (1) | MA46365A (fr) |
MX (1) | MX2019003397A (fr) |
WO (1) | WO2018064405A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008076373A1 (fr) | 2006-12-14 | 2008-06-26 | Abraxis Bioscience, Llc | Thérapie contre le cancer du sein fondée sur le statut des récepteurs hormonaux, dans laquelle sont utilisées des nanoparticules comprenant du taxane |
AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
LT3313401T (lt) | 2015-06-29 | 2022-01-10 | Abraxis Bioscience, Llc | Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui |
CA3094453A1 (fr) * | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methodes de traitement de troubles du systeme nerveux central par l'intermediaire de l'administration de nanoparticules d'un inhibiteur de mtor et d'une albumine |
JP2021526138A (ja) * | 2018-05-22 | 2021-09-30 | アブラクシス バイオサイエンス, エルエルシー | 肺高血圧症を処置するための方法および組成物 |
CN113795287A (zh) * | 2019-03-19 | 2021-12-14 | 阿布拉科斯生物科学有限公司 | 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 |
WO2021086946A1 (fr) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Compositions pharmaceutiques d'albumine et de rapamycine |
CN111621556A (zh) * | 2019-12-31 | 2020-09-04 | 安徽医科大学第一附属医院 | 一种检测人线粒体atp6基因8993位点基因型的试剂盒及方法 |
CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
CN114507677B (zh) * | 2022-02-16 | 2023-09-05 | 中国人民解放军空军军医大学 | Ndufs1基因在治疗心梗后心衰中的应用和相关产品 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014222A2 (fr) * | 2002-08-12 | 2004-02-19 | The Regents Of The University Of Michigan | Diagnostic et traitement de maladies engendrees par des anomalies propres au trajet de la sclerose tubereuse (de bourneville) |
WO2006094236A1 (fr) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine |
US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
JP2010520289A (ja) * | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス, エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
CA2686736A1 (fr) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Compositions de nanoparticules comprenant de la rapamycine pour le traitement de l'hypertension pulmonaire |
US20120064143A1 (en) * | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
AU2011232862B2 (en) * | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
SG10201606406PA (en) * | 2011-04-28 | 2016-09-29 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
WO2013024467A2 (fr) * | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Protéines ribosomales mitochondriales en tant que régulateurs du vieillissement |
EP2968191B1 (fr) * | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Méthodes de traitement du cancer de la vessie |
EP3068435A1 (fr) | 2013-11-13 | 2016-09-21 | Novartis AG | Inhibiteurs de mtor ameliorant la reponse immunitaire |
WO2016134486A1 (fr) | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Utilisation de canagliflozine et de ses dérivés dans le traitement du cancer |
WO2017096270A1 (fr) * | 2015-12-03 | 2017-06-08 | The Regents Of The University Of California | Méthodes de traitement de maladies mitochondriales |
-
2017
- 2017-09-28 EP EP17857459.6A patent/EP3518923A4/fr active Pending
- 2017-09-28 KR KR1020197011866A patent/KR102475256B1/ko active IP Right Grant
- 2017-09-28 AU AU2017335902A patent/AU2017335902B2/en active Active
- 2017-09-28 JP JP2019516447A patent/JP2019529474A/ja active Pending
- 2017-09-28 EA EA201990820A patent/EA201990820A1/ru unknown
- 2017-09-28 CA CA3038824A patent/CA3038824A1/fr active Pending
- 2017-09-28 MA MA046365A patent/MA46365A/fr unknown
- 2017-09-28 WO PCT/US2017/054149 patent/WO2018064405A1/fr active Application Filing
- 2017-09-28 BR BR112019006113A patent/BR112019006113A2/pt active Search and Examination
- 2017-09-28 CN CN201780072508.4A patent/CN110022876A/zh active Pending
- 2017-09-28 KR KR1020227042293A patent/KR20230003239A/ko not_active Application Discontinuation
- 2017-09-28 MX MX2019003397A patent/MX2019003397A/es unknown
- 2017-09-28 US US16/336,390 patent/US20190307732A1/en not_active Abandoned
-
2019
- 2019-03-24 IL IL265566A patent/IL265566A/en unknown
- 2019-03-26 CL CL2019000787A patent/CL2019000787A1/es unknown
-
2022
- 2022-09-16 JP JP2022148199A patent/JP2022191238A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019006113A2 (pt) | 2019-06-18 |
JP2019529474A (ja) | 2019-10-17 |
KR102475256B1 (ko) | 2022-12-08 |
CL2019000787A1 (es) | 2019-05-31 |
AU2017335902A1 (en) | 2019-04-18 |
WO2018064405A1 (fr) | 2018-04-05 |
EA201990820A1 (ru) | 2019-10-31 |
CA3038824A1 (fr) | 2018-04-05 |
IL265566A (en) | 2019-05-30 |
CN110022876A (zh) | 2019-07-16 |
KR20230003239A (ko) | 2023-01-05 |
KR20190060797A (ko) | 2019-06-03 |
JP2022191238A (ja) | 2022-12-27 |
AU2017335902B2 (en) | 2023-08-24 |
US20190307732A1 (en) | 2019-10-10 |
EP3518923A1 (fr) | 2019-08-07 |
MX2019003397A (es) | 2019-06-06 |
EP3518923A4 (fr) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46365A (fr) | Méthodes de traitement de troubles mitochondriaux et métaboliques | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
FR24C1025I1 (fr) | Compositions et méthodes de traitement de l'anémie | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA45192A (fr) | Traitement d'association | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
DK3125882T3 (da) | Behandling af metabolske lidelser i hestedyr | |
HK1243636A1 (zh) | 用於治療代謝疾病和癌症的新的線粒體解偶聯劑 | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
MA43532A (fr) | Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MA42930A (fr) | Traitement de maladies neurodégénératives | |
MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
MA42985A (fr) | Traitement de troubles liés à l'acide biliaire | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
FR3044227B1 (fr) | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires | |
DK3458067T3 (da) | Behandling af neurologiske lidelser | |
MA40869A (fr) | Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar | |
IL260987A (en) | Treatment and diagnosis of inflammatory disorders | |
MA48625A (fr) | Composés et méthodes de traitement de la douleur viscérale |